Home » Pharmaceuticals

PharmSource – Cell Therapy Market Opportunity for CMOs – 2018 Edition

This PharmSource Trend Report will explore whether the bio/pharma industry is adequately prepared for future cell therapy developments and whether pharma companies and CDMOs are making appropriate investments in the capacity and technology to support the coming opportunity. In particular, this Trend Report seeks to achieve the following objectives:

a. To describe and evaluate the cell therapy market opportunity;

b. To describe and address the adequacy of the network of CDMOs that manufacture for the cell therapy market, both clinical and commercial;

c. To assess the outlook for buyers and sellers of contract manufacturing services for cell therapies, including the supply/demand balance.


Who should buy this report?

This 35-page report gives important, expert insight you won’t find in any other source. 16 tables and figures throughout the report illustrate major points and trends. This report is required reading for:

• CMO executives who must have deep understanding of the Cell Therapy marketplace to make strategic planning and investment decisions.

• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.

• Pharmaceutical and Biotech companies involved in the development of Cell Therapies or Cell Therapy technologies.

• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Key Players


China PLA General Hospital


3P Biopharmaceuticals


Anemocyte SRL

apceth Biopharma GmbH

Areta International

Army Military Medical University (formerly Third Military Medical University)


Atvio Biotech Ltd

Austrianova Singapore Pte. Ltd.


Bio Elpida

Bioinova sro

Brammer Bio



Cell and Gene Therapy Catapult


Cellin Technologies LLC

Cellular Therapeutics Ltd.


City of Hope

Cognate Bioservices

Cook General BioTechnology, LLC

Dendreon Pharmaceuticals LLC


Fraunhofer Group

GE Healthcare


Gilead Sciences Inc.

Histocell SL

Hitachi Chemical Co Ltd

Hitachi Chemical Co., Ltd.

Holostem Terapie Avanzate

Incell Corporation LLC

International Stem Cell Corporation

Japan Tissue Engineering

Johnson & Johnson

KBI Biopharma


Kite Pharma Inc.

Lonza Group

Lonza Netherlands



MolMed SpA

New York Blood Center, Inc

Newcastle University

NHS Blood and Transplant

Nikon Corporation

Novartis International AG

Novartis Pharmaceuticals Corp.

Organogenesis Inc.

Oxford Biomedica


Provia Laboratories LLC

Roslin Cell Therapies

Sanpower Group Co Ltd

Sanquin Blood Supply Foundation

Shenzhen Geno-Immune Medical Institute

Stem Cell and Cancer Institute (SCI)

Takara Bio

University College London

University of Edinburgh

University of Miami Health System

University of Minnesota

University of Pittsburgh

University of Utah Health

Vericel Corp.

WuXi AppTec


Table of Contents

Table of Contents

1. Executive Summary 4

2. Introduction 5

3. Commercial Cell Therapy Experience 7

4. Cell Therapy Pipeline 10

5. Next-Generation Technologies 13

6. Approvals Outlook 15

7. Cell Therapy Supply Chain 16

8. Demand Models 23

9. What It Means 25

10. Notes on Methodology 28

11. Appendix 32

List of Tables

List of Tables

Table 1 : FDA-Approved, Marketed Cell Therapies 7

Table 2: Cell Therapy Approvals 15

Table 3: Cell Therapy CDMOs’ Biological Services 17

Table 5: Cell Therapy CDMOs’ Packaging Capabilities 19

Table 6: Cell Therapy CDMO Sites and Associated Cell Source and Types 21

Table 7: Method of Transfection Used at Cell Therapy CDMO Sites 23

Table 8: Model for Cell Therapy Clinical Requirements 24

Table 9: Model for Cell Therapy Commercial Requirements 25

Table 10: Model for Yearly Cell Therapy Commercial Requirements 31

List of Figures

List of Figures

Figure 1: Kymriah Global Sales Forecast 2018–2024 ($B) 8

Figure 2: Yescarta Global Sales Forecast 2018–2024 ($B) 9

Figure 3: Pipeline Cell Therapy Candidates 10

Figure 4: Phase I Trial Starts by Sponsor Type 11

Figure 5: Phase II Planned Trial Starts by Sponsor Type 12

Figure 6: Phase III Planned Trial Starts by Sponsor Type 12


Discounts available for multiple purchases.

+44 20 7947 2960

Join our mailing list

Saved reports